Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
ViroPharma Inc.
Type
Public NASDAQ Biotechnology Index
Traded as NASDAQ: VPHM
Industry Healthcare, Biotechnology, Pharmaceutical company
Founded Exton, Pennsylvania, U.S. (1994)
Headquarters Exton, Pennsylvania, U.S.
Key people
Claude H. Nash (founding CEO)
Vincent Milano, Chairman and CEO
Products Vancocin
Revenue 132,417,000 USD (2005)
Operating income
88,145,000 USD (2005)
Net income
113,705,000 USD (2005)
Number of employees
232
Website www.viropharma.com

ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.

Investment goal date:
Dividends reinvested
ViroPharma Inc. VPHM report
Period
Date
Adjusted Actuals EPS
GAAP EPS
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Major Shareholders
Name Relationship
Total Shares
Holding stocks